首页> 外国专利> Method for the diagnosis of papillary renal cell carcinoma and a kit for its implementation

Method for the diagnosis of papillary renal cell carcinoma and a kit for its implementation

机译:诊断乳头状肾细胞癌的方法及其试剂盒

摘要

1. A method for diagnosing papillary renal cell carcinoma (PPC), comprising the following steps: a) obtaining an initial pair of tissue samples from a patient, where one of the samples was obtained from tissue suspected of being affected by cancer, and the second was obtained from adjacent histologically normal tissue (“conditional norm”) ; b) isolation and purification of RNA preparations from the initial pair of samples; c) synthesis of single-stranded or double-stranded cDNA on an RNA matrix using oligonucleotide primers; d) quantitative amplification of the on CALL using the cDNA obtained in step c) as a template and a pair of gene-specific oligonucleotide primers SEQ ID NO: 1 and 2; e) comparing the amount of amplified CALL DNA fragment for a sample obtained from tissue suspected of being affected by cancer with the amount of amplified a DNA fragment for a sample obtained from normal tissue, where the indicated amounts of the amplified DNA fragment reflect a change in the CALL gene mRNA content, and a decrease in the CALL gene mRNA is a diagnostic sign of AUC. . The method of claim 1, wherein the sequence of primers and probe is represented by SEQ ID NO: 1, 2, and 3.3. The method of claim 1, wherein, in step d), the quantitative amplification reaction of the CALL gene fragment is real-time PCR. The method of claim 1, wherein in step e), GUSB and / or RPN1 genes encoding beta-glucuronidase and riboforin 1, respectively, are used as internal control for kidney tissue. A set of primers and probe for real-time polymerase chain reaction for the quantitative assessment of the mRNA content of the CALL gene having the sequence of SEQ ID NO: 1, 2 and 3.
机译:1.一种诊断乳头状肾细胞癌(PPC)的方法,包括以下步骤:a)从患者获得初始的一对组织样品,其中一个样品是从怀疑受癌症影响的组织中获得的,并且第二个是从相邻的组织学正常组织中获得的(“条件规范”); b)从最初的一对样品中分离和纯化RNA制剂; c)使用寡核苷酸引物在RNA基质上合成单链或双链cDNA; d)使用步骤c)中获得的cDNA作为模板和一对基因特异性寡核苷酸引物SEQ ID NO:1和2,对CALL上的CALL进行定量扩增; e)比较从怀疑受癌症影响的组织获得的样品中扩增的CALL DNA片段的量与从正常组织获得的样品中扩增的DNA片段的量,其中所示的扩增DNA片段量反映了变化CALL基因mRNA含量下降,而CALL基因mRNA下降则是AUC的诊断指标。 。 2.根据权利要求1所述的方法,其中,所述引物和探针的序列由SEQ ID NO:1、2和3.3表示。 2.根据权利要求1所述的方法,其中,在步骤d)中,所述CALL基因片段的定量扩增反应是实时PCR。 2.权利要求1的方法,其中在步骤e)中,分别编码β-葡糖醛酸糖苷酶和核糖蛋白1的GUSB和/或RPN1基因用作肾脏组织的内部对照。用于实时聚合酶链反应的一组引物和探针,用于定量评估具有SEQ ID NO:1、2和3的CALL基因的mRNA含量。

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号